Spots Global Cancer Trial Database for Study to Evaluate the Safety and Anti-tumor Activity of SCC244
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Evaluate the Safety and Anti-tumor Activity of SCC244
Official Title: A Phase I Trial to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of SCC244 in Subjects With Advanced Solid Tumors
Study ID: NCT03466268
Conditions
Interventions
Study Description
Brief Summary: This study evaluates the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of SCC244 in patients with advanced solid tumors with c-Met Alterations.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Guangdong General Hospital, Guangzhou, Guangzhou, China
Contact Details
Name: Yilong Wu, M.D.
Affiliation: Guangdong Provincial People's Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
